Next Article in Journal
Results of surgical treatment of aortic root infection
Previous Article in Journal
The evaluation of knowledge and activities of primary health care professionals in promoting breast-feeding
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Use of recombinant activated factor VII

1
Department of Intensive Care
2
Department of Physiology, Kaunas University of Medicine, Lithuania
*
Author to whom correspondence should be addressed.
Medicina 2009, 45(3), 248; https://doi.org/10.3390/medicina45030032
Received: 20 October 2008 / Accepted: 11 February 2009 / Published: 16 February 2009
Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and acquired hemostatic disorders for more than 10 years. Hemostasis is initiated by the FVIIa bound to tissue factor (TF), which constitutes only approximately 1% of total amount of the FVII protein existing in the blood. rFVII becomes activated only after the binding to the TF, released at the site of tissue injury. The efficiency of rFVIIa in the treatment of such life-threatening hemorrhagic states like hemophilia reaches up to 76–84%. rFVIIa is successfully used in the treatment of congenital deficiency of factor VII. It normalizes prothrombin time in the patients with the liver diseases and in cases of overdose of indirect anticoagulants. It is also useful for patients suffering from thrombocytopenia, thrombocyte function disorders, hemophilia A and B with development of inhibitors. rFVIIa allows overcoming uncontrollable hemorrhages, etc. It is supposed that rFVIIa is becoming a universal hemostatic drug.
Keywords: hemorrhage; hemostasis; bleeding; hemophilia; recombinant activated factor VII hemorrhage; hemostasis; bleeding; hemophilia; recombinant activated factor VII
MDPI and ACS Style

Reingardienė, D.; Lažauskas, R. Use of recombinant activated factor VII. Medicina 2009, 45, 248.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop